Sanofi Shares Rise After Dupixent Trial Hits Targets, Adding to Drug Potential
March 23 2023 - 07:08AM
Dow Jones News
By Adria Calatayud
Shares in Sanofi SA rose Thursday after the French
pharmaceutical company and Regeneron Pharmaceuticals Inc. said
their jointly developed Dupixent drug showed potential to treat
chronic obstructive pulmonary disease in a late-stage trial.
At 1034 GMT, Sanofi shares traded 5% higher at 95.38 euros
($103.44).
Sanofi and Regeneron said Dupixent met the primary and all key
secondary objectives in a Phase 3 trial, and that this made it the
first biologic to show clinically meaningful reduction in
exacerbations of COPD, as well as significant improvements in lung
function, compared to placebo.
Patients who received the drug in the trial experienced a 30%
reduction in moderate or severe acute COPD exacerbations over 52
weeks, the companies said.
This is the seventh disease against which Dupixent has shown
positive results, Sanofi and Regeneron said. The companies jointly
developed the drug under a global collaboration agreement.
Analysts at Jefferies said in a research note that results from
the trial suggest Dupixent has blockbuster potential as a COPD
treatment, a challenging indication for which no biologic had shown
benefits to date despite numerous attempts.
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
March 23, 2023 06:53 ET (10:53 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Historical Stock Chart
From Sep 2023 to Oct 2023
Sanofi (EU:SAN)
Historical Stock Chart
From Oct 2022 to Oct 2023